Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

Core Insights - Oculis Holding AG has appointed Mark Kupersmith, M.D. as Chief Medical Advisor for Neuro-Ophthalmology and Sebastian Wolf, M.D., Ph.D. as Chief Medical Advisor for Ophthalmology, enhancing its leadership team to drive advancements in ophthalmic and neuro-ophthalmic diseases [1][5][6] Company Developments - Oculis has made significant progress in its clinical pipeline, completing enrollment in Phase 3 DIAMOND trials for OCS-01 targeting diabetic macular edema and aligning with the U.S. FDA on a genotype-based development program for Licaminlimab (OCS-02) in dry eye disease [2][4] - Positive topline results were announced for Privosegtor (OCS-05) in acute optic neuritis, marking a pivotal step towards new therapies for neuronal and axonal preservation [2][4] Leadership Expertise - Mark Kupersmith, M.D. brings over 40 years of experience in neuro-ophthalmology, with a focus on acute optic nerve disorders and significant contributions to clinical research [3][7][8] - Sebastian Wolf, M.D., Ph.D. is a distinguished expert in retina and imaging, with a strong background in clinical and scientific research, particularly in diabetic macular edema [4][10][11] Clinical Pipeline - Oculis' pipeline includes three core product candidates: OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease, with ongoing late-stage clinical trials [14]